Relation of interleukin-6 in rheumatoid arthritis patients to systemic bone loss and structural bone damage

Rheumatology International

Volumn 33, Issue 3, 2013, Pages 697-703

  Abdel Meguid, Mona Helmy ^a   Hamad, Yousry Hasan ^a   Swilam, Rania Shafek ^a   Barakat, Mohamed Samy ^a  

^a ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

Interleukin 6; Rheumatoid arthritis; Structural bone damage; Systemic bone loss

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCIUM ION; CREATININE; INTERLEUKIN 6; STEROID;

ADULT; ARTICLE; BLOOD CELL COUNT; BODY MASS; BONE DENSITY; BONE INJURY; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE DURATION; DUAL ENERGY X RAY ABSORPTIOMETRY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; LABORATORY TEST; MALE; MORNING STIFFNESS; OSTEOBLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; STEROID THERAPY; THROMBOCYTE COUNT; UREA BLOOD LEVEL;

ADRENAL CORTEX HORMONES; ADULT; ARTHRITIS, RHEUMATOID; BLOOD SEDIMENTATION; BONE DENSITY; BONE RESORPTION; C-REACTIVE PROTEIN; CALCIUM; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; OSTEOPOROSIS;

EID: 84878134773     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-012-2375-7     Document Type: Article

References (46)

1. Walsh NC, Crotti TN, Coldring SR, Gravallese EM (2005) Rheumatic diseases: the effects of inflammation on bone. Immunol Rev 208:228-251
2. Firestern GS (2003) Evolving concepts of rheumatoid arthritis. Nature 423:356-361
3. Mikuls TR (2003) Co-morbidity in rheumatoid arthritis. Best Pract Res Clin Rheumatol 17:729-752
4. Young A, Koduri G (2007) Extra-articular manifestations and complications of rheumatoid arthritis. Best Pract Res Clin Rheumatol 21:907-927
5. Forsblad DH, Larsen A, Waltbrand E, Kvist G, Mellstrom D, Saxne T, Ohlsson C, Nordborg E, Carlsten H (2003) Radiographic joint destruction in postmenopausal rheumatoid arthritis is strongly associated with generalized osteoporosis. Ann Rheum Dis 62:617-623
6. Sinigaglia L, Varenna M, Girasole G, Bianchi G (2006) Epidemiology of osteoporosis in rheumatic diseases. Rheum Dis Clin N Am 32:631-658
7. Kroger H, Honkanen R, Saarikoski S, Alhava E (1994) Decreased axial bone mineral density in elderly women. The study of Osteoporotic Fractures Research Group. J Bone Miner Res 10:257-263
8. Lane NE, Pressman AR, Star VL, Cummings SR, Nevitt MC (1995) Rheumatoid arthritis and bone mineral density in elderly women. The study of Osteoporotic Fractures Research Group. J Bone Miner Res 10:257-263
9. Van Staa TP, Geusens P, Bijlsma JW, Leufkens HG, Cooper C (2006) Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthr Rheum 54:3104-3112
10. Emery P, Salmon M (1991) The immune response. 2, Systemic mediators of inflammation. Br J Hosp Med 45:164-168
11. Kwan TS, Padrines M, Theoleyre S, Heymann D, Fortun Y (2004) IL-6, RANKL, TNF-alpha/IL-l: inter relations in bone resorption pathophysiology. Cytokine Growth Factor Rev 15:49-60
12. Naka T, Nishimoto N, Kishimoto T (2002) The paradigm of IL-6: from basic science to medicine. Arthr Res 4(Suppl 3):S233-S242
13. De Benedetn F, Rucci N, Del Fattore A, Peruzzi B, Paro R, Longo M, Vivarelli M, Muratori F, Berni S, Ballanti P, Ferrari S, Teti A (2006) Impaired skeletal development in interleukin-6-transgenic mice, a model for the impact of chronic inflammation on the growing skeletal system. Arthr Rheum 54:3551-3563
14. Ershler WB, Harman SM, Keller ET (1997) Immunologic aspects of osteoporosis. Dev Comp Immunol 21:487-499
15. Devlin RD, Reddy SV, Savino R, Ciliberto G, Roodman GD (1998) IL-6 mediates the effects of IL-l or TNF, but not PTHrP or 1,25(OH)2D3, on osteoclast-like cell formation in normal human bone marrow cultures. J Bone Miner Res 13:393-399
16. Nakashima T, Kobayashi Y, Yamasaki S, Kawakami A, Eguchi K, Sasaki H (2000) Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Biophys Res Commun 275:768-775
17. Le Goff B, Blanchard F, Berthelot JM, Heymann D, Maugars Y (2010) Role for interleukin-6 in structural joint damage and systemic bone loss in rheumatoid arthritis. Jt Bone Spine 77(3):201-205
18. Burkhaer F, Haindl P, Maktari A, Nothngal T et al (2007) Diseases activity score-28 values differ considerably depending on patient's pain perception and sex. J Rheumatol 34:2382-2387
19. Krishman E, Tugwell F, Fries JF (2004) Percentile benchmarks in patients with rheumatoid arthritis: Health Assessment Questionnaire as quality indicator (QI). Arthr Res Ther 6:505-513
20. Dacie JV, Lewis SM (1994) Basic haematologic techniques. In: Practical haematology, 7th edn. Churchill Livingstone, Edinburg, pp 37-66
21. Sox HC, Liang MH (1986) The erythrocyte sedimentation rate. Guidelines for rational use. Ann Int Med 104(4):515-523
22. Ritche D, Boyle JA, Innes JM (1988) Clinical studies with an articular index for assessment of joint tenderness in patient with rheumatoid arthritis. Q J Med 37:393-406
23. Jones MG et al (1990) Specificity of rheumatoid factor in relation to the disease state in rheumatoid arthritis. Ann Rheum Dis 49:757-762
24. Bizzaro N et al (2001) Diagnostic accuracy of anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem 47:1089-1093
25. Ding C, Parameswaran V, Udayan R, Burgess J, Jones G (2008) Circulating levels of inflammatory markers predict change in bone mineral and resorption in older adults: a longitudinal study. J Clin Endocrinol Metab 93:1952-1958
26. Kennedy AC, Smith DA, Buchanan WW, Anderson JB, Jasani MK (1937) Bone loss in patients with rheumatoid arthritis 4:73-79
27. Harris ED Jr (1993) Etiology, pathogenesis of rheumatoid arthritis. In: Kelley WN, Harris ED Jr, Ruddy S, Sledge CB (eds) Textbook of rheumatology, vol 1, 4th edn. WB Saunders, Philadelphia, pp 833-873
28. Sambrook PN, Eisman JA, Champion GD, Yeates MG, Pocock NA, Eberl S (1987) Determinants of axial bone loss in rheumatoid arthritis. Arthr Rheum 30:721-728
29. Suzki Y, Mizushima Y (1997) Osteoporosis in rheumatoid arthritis. Osteoporos Int 7(Suppl 3):S217-S222
30. Le Goff B, Blanchard F, Berthelot JM, Heymann D, Maugars Y (2010) Role of interleukin-6 in structural and systemic bone loss in rheumatoid arthritis. Jt Bone Spine 77(3):201-205
31. Verstraeten A, Dequeker J (1986) Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis: effect of low dose corticosteroids. Ann Rheum Dis 45(10):852-857
32. Sambrook PN, Cohen ML, Eisman JA, Pocock NA, Champion GD, Yeates MG (1989) Effects of low dose corticosteroids on bone mass in rheumatoid arthritis: a longitudinal study. Ann Rheum Dis 48(7):535-538
33. Kröger H, Laitinen K (1992) Bone mineral density measured by dual-energy X-ray absorptiometry in normal men. Eur J Clin Invest 22(7):454-460
34. O'Malley M, Kenrick AJ, Sartoris DJ, Hochberg AM, Weisman MH, Ramos E, Zvaifler N, Resnick D (1989) Axial bone density in rheumatoid arthritis: comparison of dual-energy projection radiography and dual-photon absorptiometry. Radiology 170(2):501-505
35. Als OS, Gotfredsen A, Riis BJ, Christiansen C (1985) Are disease duration and degree of functional impairment determinants of bone loss in rheumatoid arthritis? Ann Rheum Dis 44(6):406-411
36. Edwards CJ, Williams E (2010) The role of interleukin-6 in rheumatoid arthritis-associated osteoporosis. Osteoporos Int 21:1287-1293
37. Giuliani N, Sansoni P, Girasole G, Vescovini R, Passeri G, Passeri M, Padrazzoni M (2010) Serum interleukin-6, soluble interleukin-6 receptor and soluble gp130 exhibit different patterns of age and menopause-related changes. Exp Gerontol 36:547-557
38. Ferrari SL, Ahn-Luong L, Garnero P, Humphries SE, Greenspan SL (2003) Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of c-reactive protein and markers of bone resorption in postmenopausal women. J Endocrinol Metab 88:225-229
39. Sambrook PN, Eisman JA, Yeates MG, Pocock NA, Eberl S, Champion GD (1986) Osteoporosis in rheumatoid arthritis: safety of low dose corticosteroids. Ann Rheum Dis 45(11):950-953
40. Hooyman JR, Melton LJ III, Nelson AM, O'Fallon WM, Riggs BL (1984) Fractures after rheumatoid arthritis. A population-based study. Arthr Rheum 27(12):1353-1361
41. Magaro M, Tricerri A, Piane D, Zoli A, Serra F, Altomonte L, Mirone L (1991) Generalized osteoporosis in non-steroid treated rheumatoid arthritis. Rheumatol Int 11(2):73-76
42. Sambrook PN, Eisman JA, Champion GD, Yeates MG, Pocock NA, Eberl S (1987) Determinants of axial bone loss in rheumatoid arthritis. Arthr Rheum 30(7):721-728
43. Reid DM, Kennedy NS, Smith MA, Nicoll J, Brown N, Tothill P, Nuki G (1986) Bone loss in rheumatoid arthritis and primary generalized osteoarthrosis: effects of corticosteroids, suppressive antirheumatic drugs and calcium supplements. Br J Rheumatol 25(3):253-259
44. Als OS, Gotfredsen A, Christiansen C (1985) The effect of glucocorticoids on bone mass in rheumatoid arthritis patients. Influence of menopausal state. Arthr Rheum 28(4):369-375
45. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodsen GC, Moffett AH et al (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821-831
46. Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, and the Denosumab Rheumatoid Arthritis Study Group et al (2008) Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelvemonth, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthr Rheum 58:1299-1309